Review
. 2020 Sep;15(4).
doi: 10.1159/000509846.

Genomic Signatures in Luminal Breast Cancer

Julian Puppe 1 Tabea Seifert 1 Christian Eichler 1 Henryk Pilch 1 Peter Mallmann 1 Wolfram Malter 1 
Affiliations
  • PMID: 32982645
  •     91 References

Abstract

Background: Breast cancer is a very heterogeneous disease and luminal breast carcinomas represent the hormone receptor-positive tumors among all breast cancer subtypes. In this context, multigene signatures were developed to gain further prognostic and predictive information beyond clinical parameters and traditional immunohistochemical markers.

Summary: For early breast cancer patients these molecular tools can guide clinicians to decide on the extension of endocrine therapy to avoid over- and undertreatment by adjuvant chemotherapy. Beside the predictive and prognostic value, a few genomic tests are also able to provide intrinsic subtype classification. In this review, we compare the most frequently used and commercially available molecular tests (OncotypeDX®, MammaPrint®, Prosigna®, EndoPredict®, and Breast Cancer Index<sup>SM</sup>). Moreover, we discuss the clinical utility of molecular profiling for advanced breast cancer of the luminal subtype.

Key Messages: Multigene assays can help to de-escalate systemic therapy in early-stage breast cancer. Only the Oncotype DX® and MammaPrint®<sup></sup>test are validated by entirely prospective and randomized phase 3 trials. More clinical evidence is needed to support the use of genomic tests in node-positive disease. Recent developments in high-throughput sequencing technology will provide further insights to understand the heterogeneity of luminal breast cancers in early-stage and metastatic disease.

Keywords: Breast cancer; Gene expression; Luminal breast cancer; Predictive biomarker; Prognostic biomarker.

Gene expression profiles from formalin fixed paraffin embedded breast cancer tissue are largely comparable to fresh frozen matched tissue.
Lorenza Mittempergher, Jorma J de Ronde, +5 authors, Laura J Van't Veer.
PLoS One, 2011 Feb 25; 6(2). PMID: 21347257    Free PMC article.
PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer.
A Prat, J S Parker, C Fan, C M Perou.
Breast Cancer Res Treat, 2012 Jul 04; 135(1). PMID: 22752290    Free PMC article.
Oncotype DX Breast Cancer recurrence score resists inter-assay reproducibility with RT2-Profiler Multiplex RT-PCR.
Verena Schildgen, Mathias Warm, Michael Brockmann, Oliver Schildgen.
Sci Rep, 2020 Jan 01; 9(1). PMID: 31889145    Free PMC article.
The landscape of cancer genes and mutational processes in breast cancer.
Philip J Stephens, Patrick S Tarpey, +60 authors, Michael R Stratton.
Nature, 2012 Jun 23; 486(7403). PMID: 22722201    Free PMC article.
Highly Cited.
Luminal A versus luminal B breast cancer: MammaTyper mRNA versus immunohistochemical subtyping with an emphasis on standardised Ki67 labelling-based or mitotic activity index-based proliferation assessment.
Kai Finsterbusch, Thomas Decker, Paul J van Diest, Cornelia M Focke.
Histopathology, 2019 Dec 18; 76(5). PMID: 31846096
Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review.
Anna Maria Militello, Teresa Zielli, +7 authors, Antonino Musolino.
Front Oncol, 2019 Aug 29; 9. PMID: 31456944    Free PMC article.
MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology.
Lorenza Mittempergher, Leonie J M J Delahaye, +18 authors, Annuska M Glas.
J Mol Diagn, 2019 Jun 08; 21(5). PMID: 31173928
Identification of molecular apocrine breast tumours by microarray analysis.
Pierre Farmer, Herve Bonnefoi, +13 authors, Richard Iggo.
Oncogene, 2005 May 18; 24(29). PMID: 15897907
Highly Cited.
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Ivana Sestak, Richard Buus, +9 authors, Mitch Dowsett.
JAMA Oncol, 2018 Feb 17; 4(4). PMID: 29450494    Free PMC article.
Highly Cited.
Gene-expression Profiling - A Decision Impact Analysis: Decision Dependency on Oncotype DX® as a Function of Oncological Work Experience in 117 Cases.
Christian Eichler, Julia Fromme, +4 authors, Wolfram Malter.
Anticancer Res, 2018 Dec 29; 39(1). PMID: 30591472
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institution's Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer.
Angela Fischer Maranta, Simon Broder, +4 authors, Thomas Ruhstaller.
Breast, 2020 Apr 18; 51. PMID: 32302928    Free PMC article.
Network-based stratification of tumor mutations.
Matan Hofree, John P Shen, +2 authors, Trey Ideker.
Nat Methods, 2013 Sep 17; 10(11). PMID: 24037242    Free PMC article.
Highly Cited.
A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response.
Oscar Krijgsman, Paul Roepman, +6 authors, Annuska M Glas.
Breast Cancer Res Treat, 2011 Aug 05; 133(1). PMID: 21814749
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
Fabrice André, Eva Ciruelos, +18 authors, SOLAR-1 Study Group.
N Engl J Med, 2019 May 16; 380(20). PMID: 31091374
Highly Cited.
An Update on Breast Cancer Multigene Prognostic Tests-Emergent Clinical Biomarkers.
André Filipe Vieira, Fernando Schmitt.
Front Med (Lausanne), 2018 Sep 21; 5. PMID: 30234119    Free PMC article.
Review.
Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.
A S Coates, E P Winer, +6 authors, Panel Members.
Ann Oncol, 2015 May 06; 26(8). PMID: 25939896    Free PMC article.
Highly Cited.
Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer.
Anna Bergamaschi, Young H Kim, +6 authors, Jonathan R Pollack.
Genes Chromosomes Cancer, 2006 Aug 10; 45(11). PMID: 16897746
Highly Cited.
West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment.
Oleg Gluz, Ulrike A Nitz, +18 authors, Nadia Harbeck.
J Clin Oncol, 2016 Mar 02; 34(20). PMID: 26926676
Highly Cited.
PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer.
Mellissa J Nixon, Luigi Formisano, +12 authors, Justin M Balko.
NPJ Breast Cancer, 2019 Sep 26; 5. PMID: 31552290    Free PMC article.
Repeated observation of breast tumor subtypes in independent gene expression data sets.
Therese Sorlie, Robert Tibshirani, +13 authors, David Botstein.
Proc Natl Acad Sci U S A, 2003 Jun 28; 100(14). PMID: 12829800    Free PMC article.
Highly Cited.
Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial.
P-L Jerevall, X-J Ma, +9 authors, O Stål.
Br J Cancer, 2011 May 12; 104(11). PMID: 21559019    Free PMC article.
The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy.
Irene De Santo, Amelia McCartney, +2 authors, Luca Malorni.
Cancers (Basel), 2019 Dec 05; 11(12). PMID: 31795152    Free PMC article.
Review.
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), R Peto, +15 authors, K Pritchard.
Lancet, 2011 Dec 14; 379(9814). PMID: 22152853    Free PMC article.
Highly Cited.
Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer.
Yanmei Wu, Yu Zhang, Hao Pi, Yuan Sheng.
Cancer Manag Res, 2020 Jun 12; 12. PMID: 32523378    Free PMC article.
Review.
Gene expression profiling predicts clinical outcome of breast cancer.
Laura J van 't Veer, Hongyue Dai, +13 authors, Stephen H Friend.
Nature, 2002 Feb 02; 415(6871). PMID: 11823860
Highly Cited.
Clinical utility of gene-expression signatures in early stage breast cancer.
Maryann Kwa, Andreas Makris, Francisco J Esteva.
Nat Rev Clin Oncol, 2017 Jun 01; 14(10). PMID: 28561071
Highly Cited. Review.
Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
Dan R Robinson, Yi-Mi Wu, +22 authors, Arul M Chinnaiyan.
Nat Genet, 2013 Nov 05; 45(12). PMID: 24185510    Free PMC article.
Highly Cited.
TAILORx: trial assigning individualized options for treatment (Rx).
Joseph A Sparano.
Clin Breast Cancer, 2006 Nov 10; 7(4). PMID: 17092406
Genomic profiling in luminal breast cancer.
Oleg Gluz, Daniel Hofmann, +3 authors, Nadia Harbeck.
Breast Care (Basel), 2014 Feb 20; 8(6). PMID: 24550749    Free PMC article.
Review.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Economic Impact of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in France.
Gregory Katz, Olivier Romano, +7 authors, Rémy Salmon.
PLoS One, 2015 Jun 19; 10(6). PMID: 26086912    Free PMC article.
Comprehensive molecular portraits of human breast tumours.
Cancer Genome Atlas Network.
Nature, 2012 Sep 25; 490(7418). PMID: 23000897    Free PMC article.
Highly Cited.
St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment.
Marija Balic, Christoph Thomssen, +2 authors, Nadia Harbeck.
Breast Care (Basel), 2019 Dec 05; 14(2). PMID: 31798382    Free PMC article.
Review.
Molecular portraits of human breast tumours.
C M Perou, T Sørlie, +15 authors, D Botstein.
Nature, 2000 Aug 30; 406(6797). PMID: 10963602
Highly Cited.
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.
Aleix Prat, Joel S Parker, +5 authors, Charles M Perou.
Breast Cancer Res, 2010 Sep 04; 12(5). PMID: 20813035    Free PMC article.
Highly Cited.
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
Fatima Cardoso, Laura J van't Veer, +32 authors, MINDACT Investigators.
N Engl J Med, 2016 Aug 25; 375(8). PMID: 27557300
Highly Cited.
Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status.
Yul Ri Chung, Hyun Jeong Kim, Min Hye Jang, So Yeon Park.
Breast Cancer Res Treat, 2016 Dec 04; 161(3). PMID: 27913931
A 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano.
N Engl J Med, 2016 Apr 07; 374(14). PMID: 27050216
Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study.
Eduardo Martínez de Dueñas, Ana Lluch Hernández, +20 authors, Ana María González-Angulo.
Breast Cancer Res Treat, 2014 Jan 15; 143(3). PMID: 24414130    Free PMC article.
Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.
Juan M Cejalvo, Eduardo Martínez de Dueñas, +24 authors, Aleix Prat.
Cancer Res, 2017 Mar 03; 77(9). PMID: 28249905    Free PMC article.
Highly Cited.
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
Mitch Dowsett, Jack Cuzick, +11 authors, Steven Shak.
J Clin Oncol, 2010 Mar 10; 28(11). PMID: 20212256
Highly Cited.
Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study.
R Wuerstlein, R Kates, +14 authors, WSG-PRIMe investigators in Germany, Austria, Switzerland.
Breast Cancer Res Treat, 2019 Feb 24; 175(2). PMID: 30796651    Free PMC article.
The impact of EndoPredict ® on decision making with increasing oncological work experience: can overtreatment be avoided?
Fabinshy Thangarajah, Christian Eichler, +6 authors, Matthias Warm.
Arch Gynecol Obstet, 2019 Feb 21; 299(5). PMID: 30783737
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2018 Jun 05; 379(2). PMID: 29860917    Free PMC article.
Highly Cited.
Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.
Miguel Martin, Jan C Brase, +15 authors, Alvaro Rodriguez-Lescure.
Breast Cancer Res, 2014 Apr 15; 16(2). PMID: 24725534    Free PMC article.
Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review.
Miho Kono, Takeo Fujii, +3 authors, Naoto T Ueno.
JAMA Oncol, 2017 Mar 17; 3(9). PMID: 28301631
Highly Cited. Review.
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +28 authors, George W Sledge.
N Engl J Med, 2015 Sep 29; 373(21). PMID: 26412349    Free PMC article.
Highly Cited.
Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris.
Laurence Slembrouck, Lauren Darrigues, +31 authors, Giuseppe Floris.
Transl Oncol, 2019 Sep 13; 12(12). PMID: 31513983    Free PMC article.
Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay.
Michaela Tsai, Shelly Lo, +11 authors, Hatem Soliman.
JAMA Oncol, 2017 Oct 28; 4(1). PMID: 29075751    Free PMC article.
HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care.
Alessandra Fabi, Anna Di Benedetto, +11 authors, Marcella Mottolese.
Clin Cancer Res, 2011 Feb 11; 17(7). PMID: 21307144
Supervised risk predictor of breast cancer based on intrinsic subtypes.
Joel S Parker, Michael Mullins, +17 authors, Philip S Bernard.
J Clin Oncol, 2009 Feb 11; 27(8). PMID: 19204204    Free PMC article.
Highly Cited.
Metaplastic breast carcinomas display genomic and transcriptomic heterogeneity [corrected]. .
Britta Weigelt, Charlotte K Y Ng, +8 authors, Jorge S Reis-Filho.
Mod Pathol, 2014 Nov 22; 28(3). PMID: 25412848    Free PMC article.
Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test.
Ralf Kronenwett, Kerstin Bohmann, +16 authors, Carsten Denkert.
BMC Cancer, 2012 Oct 09; 12. PMID: 23039280    Free PMC article.
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
Dennis C Sgroi, Ivana Sestak, +9 authors, Mitch Dowsett.
Lancet Oncol, 2013 Sep 17; 14(11). PMID: 24035531    Free PMC article.
Highly Cited.
Targeting Apoptosis: A New Paradigm for the Treatment of Estrogen Receptor-Positive Breast Cancer.
Joshua Z Drago, Sarat Chandarlapaty, Komal Jhaveri.
Cancer Discov, 2019 Mar 03; 9(3). PMID: 30824486
Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens.
Torsten Nielsen, Brett Wallden, +7 authors, James Storhoff.
BMC Cancer, 2014 Mar 15; 14. PMID: 24625003    Free PMC article.
Highly Cited.
Distribution of the 21-Gene Breast Recurrence Score in Patients with Primary Breast Cancer in Germany.
Vincent P Walter, Florin-Andrei Taran, +6 authors, Andreas Daniel Hartkopf.
Geburtshilfe Frauenheilkd, 2020 Jun 23; 80(6). PMID: 32565552    Free PMC article.
Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype.
Masumi Yanagawa, Kenzo Ikemot, +6 authors, Kohsuke Sasaki.
BMC Res Notes, 2012 Jul 27; 5. PMID: 22830453    Free PMC article.
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
G Curigliano, H J Burstein, +52 authors, B Xu.
Ann Oncol, 2017 Aug 26; 28(8). PMID: 28838210    Free PMC article.
Highly Cited.
Subtypes in BRCA-mutated breast cancer.
Ida Marie H Sønderstrup, Maj-Britt R Jensen, +6 authors, Anne-Vibeke Lænkholm.
Hum Pathol, 2018 Oct 21; 84. PMID: 30342055
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
Mitch Dowsett, Ivana Sestak, +7 authors, Jack Cuzick.
J Clin Oncol, 2013 Jul 03; 31(22). PMID: 23816962
Highly Cited.
Immune gene expression profiling reveals heterogeneity in luminal breast tumors.
Bin Zhu, Lap Ah Tse, +31 authors, Xiaohong R Yang.
Breast Cancer Res, 2019 Dec 21; 21(1). PMID: 31856876    Free PMC article.
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.
Torsten O Nielsen, Joel S Parker, +12 authors, Matthew J Ellis.
Clin Cancer Res, 2010 Sep 15; 16(21). PMID: 20837693    Free PMC article.
Highly Cited.
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
T Sørlie, C M Perou, +14 authors, A L Børresen-Dale.
Proc Natl Acad Sci U S A, 2001 Sep 13; 98(19). PMID: 11553815    Free PMC article.
Highly Cited.
How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists.
Zsuzsanna Varga, Joachim Diebold, +16 authors, Hans-Anton Lehr.
PLoS One, 2012 Jun 05; 7(5). PMID: 22662150    Free PMC article.
Impact of tissue-based genomic profiling on clinical decision making in the management of patients with metastatic breast cancer at academic centers.
Cesar A Santa-Maria, Megan Kruse, +7 authors, Alberto J Montero.
Breast Cancer Res Treat, 2017 Jul 29; 166(1). PMID: 28752189
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, +11 authors, Pierfranco Conte.
N Engl J Med, 2017 Jun 06; 377(6). PMID: 28578601
Highly Cited.
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2019 Jun 04; 380(25). PMID: 31157962    Free PMC article.
Highly Cited.
Hallmarks of 'BRCAness' in sporadic cancers.
Nicholas Turner, Andrew Tutt, Alan Ashworth.
Nat Rev Cancer, 2004 Oct 29; 4(10). PMID: 15510162
Highly Cited. Review.
A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study.
C A Drukker, J M Bueno-de-Mesquita, +10 authors, S C Linn.
Int J Cancer, 2013 Feb 02; 133(4). PMID: 23371464    Free PMC article.
Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019).
Diana Lüftner, Ingo Bauerfeind, +21 authors, Marc Thill.
Breast Care (Basel), 2019 Dec 05; 14(5). PMID: 31798392    Free PMC article.
Review.
Budget impact analysis of gene expression tests to aid therapy decisions for breast cancer patients in Germany.
M P Lux, N Nabieva, +4 authors, M G Schrauder.
Breast, 2017 Nov 13; 37. PMID: 29128582
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
M Gnant, M Filipits, +22 authors, Austrian Breast and Colorectal Cancer Study Group.
Ann Oncol, 2013 Dec 19; 25(2). PMID: 24347518
Highly Cited.
Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others.
John M S Bartlett, Jane Bayani, +18 authors, OPTIMA TMG.
J Natl Cancer Inst, 2016 May 01; 108(9). PMID: 27130929    Free PMC article.
West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer.
Ulrike Nitz, Oleg Gluz, +18 authors, West German Study Group PlanB Investigators.
J Clin Oncol, 2019 Feb 21; 37(10). PMID: 30785826
The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer.
Martin Filipits, Torsten O Nielsen, +22 authors, Austrian Breast and Colorectal Cancer Study Group.
Clin Cancer Res, 2014 Feb 13; 20(5). PMID: 24520097
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.
Koei Chin, Sandy DeVries, +21 authors, Joe W Gray.
Cancer Cell, 2006 Dec 13; 10(6). PMID: 17157792
Highly Cited.
Extensive Transcriptomic and Genomic Analysis Provides New Insights about Luminal Breast Cancers.
Inna Tishchenko, Heloisa Helena Milioli, Carlos Riveros, Pablo Moscato.
PLoS One, 2016 Jun 25; 11(6). PMID: 27341628    Free PMC article.
A gene-expression signature as a predictor of survival in breast cancer.
Marc J van de Vijver, Yudong D He, +18 authors, René Bernards.
N Engl J Med, 2002 Dec 20; 347(25). PMID: 12490681
Highly Cited.
Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. late recurrences.
Daniel F Hayes.
Breast, 2015 Aug 05; 24 Suppl 2. PMID: 26238437
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse.
Claudette Falato, Nicholas P Tobin, +3 authors, Theodoros Foukakis.
Mol Oncol, 2015 Dec 15; 10(4). PMID: 26651914    Free PMC article.
Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker.
Dennis C Sgroi, Erin Carney, +16 authors, Paul E Goss.
J Natl Cancer Inst, 2013 Jul 03; 105(14). PMID: 23812955    Free PMC article.
The molecular diversity of Luminal A breast tumors.
Giovanni Ciriello, Rileen Sinha, +5 authors, Nikolaus Schultz.
Breast Cancer Res Treat, 2013 Oct 08; 141(3). PMID: 24096568    Free PMC article.
The molecular profile of luminal B breast cancer.
Chad J Creighton.
Biologics, 2012 Sep 08; 6. PMID: 22956860    Free PMC article.
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Jennifer K Litton, Hope S Rugo, +15 authors, Joanne L Blum.
N Engl J Med, 2018 Aug 16; 379(8). PMID: 30110579
Highly Cited.
Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer.
Giovanni Ciriello, Michael L Gatza, +30 authors, Charles M Perou.
Cell, 2015 Oct 10; 163(2). PMID: 26451490    Free PMC article.
Highly Cited.
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.
Christina Curtis, Sohrab P Shah, +29 authors, Samuel Aparicio.
Nature, 2012 Apr 24; 486(7403). PMID: 22522925    Free PMC article.
Highly Cited.
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.
Martin Filipits, Margaretha Rudas, +25 authors, EP Investigators.
Clin Cancer Res, 2011 Aug 03; 17(18). PMID: 21807638
Highly Cited.
Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.
Richard Buus, Ivana Sestak, +7 authors, Mitch Dowsett.
J Natl Cancer Inst, 2016 Jul 13; 108(11). PMID: 27400969    Free PMC article.
Highly Cited.